Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
By J. Dipersio, E. Stadtmauer, A. Nademanee, I. Micallef, P. Stiff, J. Kaufman, R. Maziarz, C. Hosing, Stefan Früehauf, M. Horwitz and 3 more. Blood, 2009
757 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/17492be1b5a55c4931b4d9feed02f6e632d6975c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Thomas J. Smith
- Kari Bohlke
- G. Lyman
- K. Carson
- J. Crawford
- Scott J. Cross
- J. Goldberg
- N. Leighl
Citations in the corpus
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015, methodology): “The combination of a G-CSF and plerixafor has been evaluated in two phase III clinical trials.(47,48) Compared with a G-CSF alone, the combination of a G-CSF and plerixafor increased the number of patients who reached optimal CD34 cell targets within a specified number of apheresis days.”